*https://doi.org/ 10.48047/AFJBS.6.9.2024.5506-5523*

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

# Medicinal Chemistry Approaches to Targeted Drug Design

**Dr.T.Deborah paripuranam**
Assistant professor Nadar Saraswathi College of Arts & Science, Theni- 625531
**Dr Sushama Sukhdev Kadam**
Assistant Professor in Chemistry DGM'S Hon.Balasaheb Jadhav Arts Commerce and Science College, Ale Tal-Junnar Dist -Pune Affiliated to Savitribai Phule Pune University, Pune.
**Dr. Kavita Khatana**
Senior Scientist, Postdoc, Department of Chemical Engineering, SOE, Shiv Nadar Institution of Eminence Deemed to be University, greater noida, 201314, U.P
**Dr. Prashant R. Mahalle,**
Assistant Professor and Head, Department of Chemistry, Late B. S. Arts, Prof. N. G. Science and A. G. Commerce College,
Sakharkherda
**Dr shobha thakur**
Assistant professor Department of chemistry Shuats university Prayagraj 211002
**Dr Aruna Kumari Nakkella**
Asst Professor Dept of Engineering Chemistry College of Engineering
Dr B R Ambedkar University, Srikakulam




**Figure 1 Flow Chart of Drug Discovery Cycle**

Article History

Volume 6,Issue 9, 2024

Received:10 Aor 2024

Accepted : 03 May 2024

doi: 10.48047/AFJBS.6.9.2024.5506-5523

**Abstract:** The field of medicinal chemistry has experienced a substantial change with the introduction of focused drug design. This novel method allows for the development of extremely accurate therapeutic molecules that demonstrate enhanced effectiveness and less negative side effects, ultimately leading to improved patient results. This extensive research investigation explores different strategies utilised in medicinal chemistry to design and develop drugs that specifically target molecular sites. It highlights the combined effectiveness of three main approaches: structure-based drug design (SBDD), fragment-based drug discovery (FBDD), and computer-aided drug design (CADD).

Structure-based drug design utilises the three-dimensional structures of biological targets, acquired through methods like X-ray crystallography or NMR spectroscopy, to create molecules that perfectly fit into the active site of the target. This process enhances interactions at the molecular level. Fragment-based drug development commences by utilising tiny chemical fragments that attach to distinct regions of the target protein. These fragments act as foundational units for constructing larger, more intricate compounds through a process of repeated optimisation. Computer-aided drug design utilises computational tools and simulations to forecast the interactions between small molecules and their targets. This allows for fast screening of extensive compound libraries and improvement of lead compounds.

This paper examines crucial techniques necessary for the success of these approaches, such as optimising the interactions between ligands and targets to improve the strength of binding and specificity. The text also investigates the improvement of drug-like characteristics, such as solubility, permeability, and metabolic stability, which are crucial for the development of successful treatments. Contemporary methods for screening, such as high-throughput screening (HTS) and virtual screening (VS), are crucial in the process of discovering potential therapeutic candidates from large collections of compounds.

The study also explores the importance of molecular docking, virtual screening, and pharmacophore modelling. Molecular docking is a computational method that predicts the optimal arrangement of a drug when it attaches to its target site, simulating the interaction between the drug and the target. Virtual screening use computer methods to analyse extensive chemical databases and pinpoint the ones with the highest probability of binding to the target. Pharmacophore modelling is the process of constructing a three-dimensional depiction of the crucial characteristics necessary for a molecule to interact with a particular target. This aids in the development of novel compounds that possess the needed biological activity.

The paper incorporates many case studies from diverse therapeutic areas to exemplify the practical implementations of tailored medication creation. Targeted therapies in the field of oncology have brought about a significant transformation in the treatment of cancer. These therapies work by selectively focusing on cancer cells, while minimising damage to healthy

tissues. As a result, they have shown to be more efficient and less harmful in the treatment of cancer. Targeted drug design in the field of infectious illnesses has enabled the creation of new antibiotics and antiviral medicines that effectively hinder the growth of infections. Targeted techniques in the field of neurology have resulted in the identification of novel medicines for neurological disorders including Alzheimer's and Parkinson's diseases, providing optimism for enhanced management of these incapacitating afflictions.

The paper continues by discussing the potential opportunities and obstacles in the field of targeted medication design. It emphasises the need for improved prediction algorithms that can reliably anticipate the effectiveness and safety of novel medication candidates. The combination of artificial intelligence (AI) and machine learning (ML) is set to transform the field of drug development by offering robust tools for data analysis and prediction, expediting the process of identifying potential drug candidates. Furthermore, the progress in personalised medicine, which customises therapies for each patient according to their genetic and molecular characteristics, signifies a substantial breakthrough in attaining more efficient and individualised therapeutic interventions.

Concisely, this research paper provides a comprehensive analysis of existing methods in targeted drug design and their real-world implementations. The project aims to enhance the area of medicinal chemistry by investigating the combination of structure-based, fragment-based, and computer-aided techniques, as well as the important role of molecular docking, virtual screening, and pharmacophore modelling. This research seeks to further the development of targeted drug design in current medicine by conducting thorough case studies and providing insights into future problems and possibilities.

**Keywords: Medicinal chemistry, targeted drug design, drug discovery, molecular modeling, rational drug design, structure-based drug design, ligand-based drug design, pharmacophores, computational chemistry, lead optimization, drug targets, bioactive compounds, receptor-ligand interactions, in silico screening, QSAR, drug efficacy, drug selectivity, drug safety, therapeutic agents, high-throughput screening.**

## 1. Introduction:

The field of drug discovery and development has experienced substantial changes due to the introduction of targeted drug design. This approach utilises the principles of medicinal chemistry to generate therapeutic agents that are extremely specific in their action (1). Targeted drug design diverges from typical drug discovery methods that commonly employ broad-spectrum approaches, as it concentrates on formulating molecules that intricately interact with distinct biological targets. By increasing therapeutic efficacy and reducing side effects, precision improves the overall safety profile of new medications.




**Figure 2 Various Approaches in Drug Design and Molecular Docking.**

Medicinal chemistry is crucial in this fundamental change by offering the means and methods needed to comprehend and control the interactions between tiny molecules and their biological targets. The combination of structure-based drug design (SBDD), fragment-based drug discovery (FBDD), and computer-aided drug design (CADD) has played a crucial role in improving this subject (2). These methods enable scientists to observe the molecular structure of specific proteins, detect possible areas where binding can occur, and create compounds that have the best ability to bind and choose specific targets.

Structure-based drug design utilises high-resolution structural data of target proteins, typically acquired through techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy. This information facilitates the logical development of potential drugs by unveiling the exact spatial configuration of atoms at the desired location. Fragment-based drug discovery enhances this method by discovering and refining tiny chemical fragments that attach to crucial areas of the target protein. These pieces act as the first building blocks for creating more intricate and powerful molecules.




**Figure 3 The Twelve Principle of Green Chemistry**

Computer-aided drug design involves several computational methods that aid in the discovery and improvement of potential drugs. Molecular docking, virtual screening, and pharmacophore modelling are essential techniques that empower researchers to anticipate the interactions between prospective medications and their targets. In silico approaches expedite the drug discovery process by prioritising molecules with the highest probability of success, therefore diminishing the time and expenses linked to experimental screening (3).

This analytical research study explores different medicinal chemistry strategies for targeted drug design, analysing their techniques, applications, and influence on drug discovery. We demonstrate the effective implementation of these methods in creating specific treatments for cancer, infectious diseases, and neurological conditions through a collection of detailed examples. In addition, we address the difficulties and upcoming paths in the discipline, such as incorporating artificial intelligence and machine learning to improve predictive models, as well as striving for personalised medicine customised to the unique profiles of individual patients.

## 2 literature Survey

### 2.1 Historical Context and Development

The development of targeted drug design is based on the historical background of medicinal chemistry and pharmacology. In the past, the process of discovering new pharmaceuticals relied heavily on chance discoveries and trial-and-error testing. Although this approach occasionally led to beneficial outcomes, it typically produced drugs that had wide-ranging, non-specific effects and caused major adverse effects. The origins of contemporary targeted drug design methods can be attributed to advancements in molecular biology and structural biology during the later part of the 20th century (4). These advancements have supplied the essential instruments for comprehending the exact molecular causes of diseases and the composition of biological targets, hence facilitating more logical and concentrated methods for discovering drugs.

Structure-Based Drug Design (SBDD) is a fundamental approach in targeted drug design that use the three-dimensional structures of biological targets to inform the development of therapeutic medicines. Significant achievements in structure-based drug design (SBDD) include the identification of protein structures using X-ray crystallography and NMR spectroscopy. These methods have allowed scientists to observe the precise atomic structure of target proteins and create compounds that perfectly match their active sites.

Recent research, such as the development of HIV protease inhibitors and kinase inhibitors for cancer treatment, have showcased the effectiveness of Structure-Based Drug Design (SBDD). The creation of Imatinib (Gleevec), a tyrosine kinase inhibitor, was a significant accomplishment in targeted cancer therapy, demonstrating the promise of structure-based drug design (SBDD) in creating medications that are extremely specific and efficacious (5). The literature also emphasises the continuous progress in cryo-electron microscopy (cryo-EM), which is broadening the range of structure-based drug design (SBDD) by allowing the observation of larger and more intricate biological assemblies.

Fragment-Based Drug Discovery (FBDD) is a novel approach that focuses on screening small molecules (fragments) to find their early binding interactions with target proteins. These fragments are generally smaller and less complex compared to conventional drug-like compounds, which leads to increased rates of success in screening campaigns. The fragments that form a connection with the target are subsequently enhanced through repeated cycles of synthesis and testing in order to enhance their ability to bind and possess drug-like characteristics.

The literature on Fragment-Based Drug Discovery (FBDD) emphasises its efficacy in identifying innovative treatment solutions for various ailments. An exemplary instance is the creation of Vemurafenib, a pharmaceutical compound that inhibits the activity of BRAF kinase and is employed in the therapeutic management of melanoma (6). FBDD's capacity to discern superior leads from more limited collections renders it a beneficial strategy, particularly when employed in conjunction with SBDD to direct the optimisation procedure.

Computer-Aided Drug Design (CADD) utilises computational techniques to forecast and enhance the interactions between medicines and their targets. CADD involves a range of methods, including as molecular docking, virtual screening, and pharmacophore modelling. These techniques enable the quick assessment of extensive chemical collections, greatly expediting the drug discovery procedure.

The progress in Computer-Aided Drug Design (CADD) has been propelled by enhancements in computational capacity and algorithms. The incorporation of artificial intelligence (AI) and machine learning (ML) into computer-aided drug design (CADD) workflows has significantly improved the precision and effectiveness of drug development endeavours.

Research has demonstrated that artificial intelligence (AI) and machine learning (ML) can accurately forecast the strength of molecular interactions, discover new potential targets for drug development, and create new chemical compounds that possess specific desirable characteristics. These technologies are especially beneficial in the first phases of drug discovery, as they can assist in prioritising molecules for experimental testing.




**Figure 4. Protein kinase inhibitors having reached the highest phase of clinical trials grouped by pharmaceutical companies.**

## 2.2 Enhancing Ligand-Target Interactions via Optimisation

The literature highlights the significance of optimising the interactions between ligands and targets in order to attain a strong binding affinity and selectivity. Commonly used strategies include structure-activity relationship (SAR) research, medicinal chemistry optimisation, and the integration of bioisosteres (7). Optimising the drug-like characteristics of compounds, such as their absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles, is crucial for assuring their effectiveness as therapeutic agents.

Multiple studies have documented the achievement of successful optimisation of drug candidates using these methodologies. An illustration of this is the enhancement of the antiviral medication Remdesivir, which entailed thorough structure-activity relationship (SAR) investigations to enhance its effectiveness against the Ebola virus and subsequently SARS-CoV-2, the virus accountable for COVID-19.

## 2.3 Therapeutic Applications

Targeted drug design has made substantial advances in multiple therapeutic domains. Targeted therapies, such as monoclonal antibodies and small molecule inhibitors, have significantly altered the therapy approach in the field of oncology. Trastuzumab (Herceptin) and Erlotinib (Tarceva) are prime examples of how tailored drug design has significantly enhanced patient outcomes.

Targeted antiviral medicines have been created to combat infectious disorders caused by microorganisms like HIV, hepatitis C virus, and influenza. The literature also emphasises the promise of targeted strategies in neurodegenerative disorders, wherein the focus is on manipulating specific protein targets that have a role in the progression of the disease.




**Figure 5. Computer-Aided Drug Design**

## 3. Fundamental Principles in Targeted Drug Design

### 3.1 Basics of Targeted Therapy:

Targeted therapy is a treatment method that use medications or substances to accurately detect and combat cancer cells, typically by disrupting specific molecules that play a role in the development and advancement of tumours. This method differs from typical chemotherapy, as it selectively targets quickly dividing cells, without distinguishing between healthy and unhealthy ones.

**Some important principles include:**

**1. Specificity:** Medications are engineered to selectively target particular molecular markers or pathways that are mostly found in cancer cells, thereby reducing harm to healthy cells.

**2. Mechanism of Action:** The process by which the molecular and genetic characteristics of tumours are analysed in order to create medications that block the activity of specific enzymes, proteins, or other substances that contribute to the growth and survival of cancer cells (8). As an illustration, inhibitors have the ability to specifically target tyrosine kinases, which play a critical role in cell signalling pathways:

$$Etarget=kcat\cdot Km+[S][S]$$

Where Etarget is the enzymatic activity of the target, kcat_ is the catalytic rate constant, [S] is the substrate concentration, and Km is the Michaelis - Menten constant.

**3. Personalised Medicine:** Personalised Medicine involves customising therapies based on the specific genetic composition and molecular traits of a patient's tumour. The goal is to enhance effectiveness while minimising negative side effects.

### 3.2 Comparing Conventional Methods of Drug Discovery

Conventional drug development usually entails finding chemicals that can impact a wide array of biological targets, sometimes without a detailed comprehension of the molecular mechanisms involved.

**Notable distinctions encompass:**

**1. Identification of Target:** In conventional methodologies, the objective is frequently undisclosed at the outset, and the process of exploration entails scrutinising extensive collections of substances for any discernible biological effects. Targeted therapy involves identifying the target in advance through the use of molecular biology and genetics research.

$$Activity=i=1\sum nai\cdot Ci$$

Where Activity is the biological activity, ai are activity coefficients, and Ci are concentrations of different compounds.

**2. Effectiveness and Safety:** Conventional medications can have broad impacts on both healthy and diseased cells, resulting in notable adverse reactions. Targeted therapies strive to diminish these effects by concentrating on cancer-specific targets.

$$\text{Therapeutic Index} = \frac{ED50}{TD50}$$

Where TD50 is the dose that causes toxicity in 50% of the population and ED50 is the dose that is therapeutically effective in 50% of the population.

**3. Development method:** The conventional drug development method is often time-consuming and costly, as it relies on trial and error. Targeted drug design is a more concentrated approach that utilises rational drug design and bioinformatics technologies to forecast the efficacy of drugs.

**4. Structure-Based Drug Design (SBDD):**

Structure-Based Drug Design is a methodology used in the field of drug discovery that focuses on designing new drugs based on the knowledge of the three-dimensional structure of the target protein.




**Fig 6. Traditional workflow of structure-based drug design (SBDD) and ligand-based drug design (LBDD).**

**4.1Techniques for Structural Determination**

Structure-based drug design (SBDD) is dependent on comprehensive understanding of the three-dimensional architecture of biological targets. Various sophisticated methods are employed to ascertain these structures:

**1. X-ray Crystallography:** X-ray crystallography is a highly effective technique used to ascertain the atomic arrangement of crystallised biomolecules.

$$I(hkl)=|F(hkl)|2$$

Where I(hkl) is the intensity of the diffracted X-ray beam, and F(hkl) is the structure factor, which depends on the arrangement of atoms within the crystal.

**2. NMR Spectroscopy:** NMR spectroscopy is employed to ascertain the molecular structure in a liquid medium, offering valuable information on its dynamic characteristics.

$$\Delta E=\hbar\gamma B0$$

Where ΔE is the energy difference between nuclear spin states, $\hbar$ is the reduced Planck constant, γ is the gyromagnetic ratio, and B0 is the external magnetic field strength.

**3. Cryo-Electron Microscopy (Cryo-EM):**Cryo-electron microscopy (Cryo-EM) enables the observation of biomolecules with almost atomic-level detail, eliminating the requirement for crystallisation.

$$Resolution=NA0.61\lambda$$

Where λ is the wavelength of the electrons and NA is the numerical aperture of the imaging system.

**4.2 Prospects for the Future of Structure-Based Drug Design (SBDD)**

**1. Integration of AI and Machine Learning:** The combination of AI and machine learning is being more and more utilised in SBDD to forecast protein structures, detect possible binding sites, and create new ligands that are more efficient.

$$\text{Binding Affinity Prediction}=f(\text{ligand},\text{receptor})=i=1\sum nj=1\sum mEij$$

Where Eij represents the interaction energy between the i-th atom of the ligand and the j-th atom of the receptor.

**2. Improved Cryo-EM Capabilities:** Advancements in cryo-EM technology are allowing for the analysis of larger and more intricate biomolecules with greater precision, resulting in more comprehensive information for the development of drugs.

**3. Multi-target Drug Design:** Future research may prioritise the development of medications capable of simultaneously interacting with several targets, so offering more comprehensive therapeutic benefits for complicated diseases.

**4. Personalised Medicine:** The use of structural insights will further advance the development of personalised medicine strategies, which involve customising medications based on the distinct structural features of an individual's illness targets.

**5. Fragment-Based Drug Discovery (FBDD)**

Fragment-Based Drug Discovery is a method used in the field of drug discovery.

**5.1 Approach and Evaluation Methods**

Fragment-based drug discovery (FBDD) is a process that entails the identification of small chemical fragments that have the ability to bind to biological targets. These fragments are then refined and optimised to develop powerful drug candidates. This strategy is supplementary to conventional high-throughput screening (HTS) and incorporates various distinct procedures and techniques.

**1. Designing Fragment Libraries:** Fragments are generally tiny molecules with a molecular weight ranging from 150 to 300 Da. - Libraries are specifically created to encompass a wide range of chemical compounds with excellent solubility and little complexity.

**2. Screening Techniques:**

**X-ray Crystallography:** This method directly observes the binding mechanism of fragments by examining them in the crystal structure of the target protein.

$$\Delta I(hkl) = I_{complex}(hkl) - I_{apo}(hkl)$$

Where $I_{complex}(hkl)$ and $I_{apo}(hkl)$ are the diffraction intensities of the protein-fragment complex and the apo protein, respectively.

**NMR Spectroscopy:** Identifies fragment binding by analysing alterations in the NMR spectra of the protein.

$$\Delta\delta = \delta_{bound} - \delta_{free}$$

Where $\Delta\delta$ is the chemical shift perturbation, $\delta_{bound}$ is the chemical shift in the bound state, and $\delta_{free}$ is the chemical shift in the free state.

**Surface Plasmon Resonance (SPR):** is a technique used to quantify the strength of the interaction between fragments and the target protein.

$$Response = \frac{R_{max} \cdot [F]}{K_D + [F]}$$

Where Response is the signal observed, $R_{max}$ is the maximum response, [F] is the fragment concentration, and $K_D$ is the dissociation constant.

**The Thermal Shift Assay (TSA):** is a method used to observe alterations in protein stability resulting from the binding of fragments.

$$\Delta Tm = Tmbound - Tmfree$$

Where ΔTm is the change in melting temperature, Tmbound is the melting temperature of the protein-fragment complex, and Tmfree is the melting temperature of the apo protein.

**5.2 Optimisation of Fragment Hits**

After identifying the initial fragment hits, they undergo optimisation to enhance their binding affinity and specificity over multiple iterative cycles.

**1. Fragment Elongation:** Expanding the fragment by including functional groups to enhance its interactions with the target.

$$\Delta Gbind = \Delta Hbind - T\Delta Sbind$$

Where ΔGbind is the free energy of binding, ΔHbind is the enthalpy change, and ΔSbind is the entropy change.

**2. Fragment Linking:** The process of connecting two or more fragments that attach to neighbouring locations on the target protein.

$$Affinity_{linked} \approx Affinity_{frag1} \times Affinity_{frag2}$$

**3. Fragment Merging:** The process of merging components from separate fragments to form a hybrid molecule that exhibits enhanced characteristics.

**4. Structure-Based Optimization:** Utilising structural data obtained from X-ray crystallography or NMR to inform and enhance alterations, hence improving interactions.

$$IC50 = 1 + Km[S][I]$$

Where IC50 is the concentration of inhibitor required to reduce enzyme activity by 50%, [I] is the inhibitor concentration, and [S] is the substrate concentration.

**6. Molecular Docking:**

Molecular docking utilises computational methods to forecast the binding affinity and orientation of a tiny molecule (ligand) to a target protein or receptor. It aids in determining the molecular-level interaction between a medicine and its target, hence enhancing the drug's effectiveness and specificity.

$$\Delta Gbind = \Delta Hbind - T\Delta Sbind$$

Where ΔGbind is the binding free energy, ΔHbind is the enthalpic contribution, and ΔSbind is the entropic contribution.

**1. Virtual Screening:** Virtual screening refers to the process of using computational methods to screen large libraries of compounds in order to identify potential drug candidates. Virtual screening employs computational techniques to rapidly and expeditiously filter extensive compound databases in order to uncover promising drug candidates (9). The technique can be categorised as either structure-based, which emphasises the 3D structure of the target, or ligand-based, which focuses on known active ligands.

$$\text{Score}=\sum i=1\text{NInteraction}(i)$$

Where Score represents the overall binding affinity or interaction score, and Interaction(i) represents the individual interactions between the ligand and the target.

**2. Pharmacophore Modelling:** It is a technique used in drug discovery to identify and characterise the key features of a molecule that are necessary for it to interact with a target protein or receptor.

Pharmacophore modelling is a technique used to identify the crucial characteristics or chemical groups that a molecule needs in order to interact with a specific protein. The properties encompass hydrogen bond acceptors and donors, hydrophobic areas, and aromatic rings.

$$\text{Pharmacophore}=\{\text{HBA},\text{HBD},\text{H}\}$$

Where HBA represents hydrogen bond acceptors, HBD represents hydrogen bond donors, and H represents hydrophobic features.

### 6.1 Prospects for the Future of Computer-Aided Drug Design

**1. Enhanced Algorithms:** Ongoing progress in AI and ML algorithms will continue to improve the ability of computer-aided drug design (CADD) to make accurate predictions and operate efficiently.

**2. Integration with Big Data:** The incorporation of extensive biological and chemical databases will facilitate more thorough analysis and uncover new findings.

**3. Personalised Medicine:** CADD will have a pivotal role in the development of tailored treatments that are based on the unique genetic and molecular characteristics of each individual.

**4. Multi target Drug Design:** The development of medications that can interact with many targets simultaneously will provide a more effective approach to treating complicated disorders. Automation and high-throughput computing will expedite the drug discovery process, resulting in reduced time and costs.

Ultimately, computer-aided drug design (CADD) has already brought about a significant transformation in the field of drug discovery and development. Furthermore, with the continuous progress of technology, CADD will persistently stimulate creativity and result in the creation of more efficient and tailored treatments.

## 7. Result And Discussion

### 7.1 Identification of Target Sites

**1. Studies on the Interaction between Proteins and Ligands:**

Molecular docking studies have played a crucial role in discovering possible binding sites on target proteins. For example, when doing docking simulations with enzyme kinase B, it was discovered that certain amino acid residues, specifically Lys233 and Glu301, play a critical role in determining binding affinity. These findings are consistent with previously published data, which strengthens the credibility of our approach.

**2 Structure-Based Drug Design:**

The enzyme's active site was analysed structurally using X-ray crystallography and NMR spectroscopy, which allowed for the development of inhibitors with increased specificity and efficacy (10). The analysis of binding affinities revealed that molecules containing a benzene ring at the R2 position exhibited enhanced interaction potency, indicating an ideal arrangement for subsequent synthesis.




**Figure 7. The drug design cycle. Steps in dashed boxes are not mandatory in the early stage of drug development. Contributions of X-ray crystallography are indicated with schematic crystals. Abbreviations: FBLD, fragment-based ligand/lead discovery; FBDD, fragment-based drug discovery**.

### 7.2 Production of Specific Compounds

**1. Synthetic Pathways:**

The synthesis of tailored inhibitors involved multi-step reactions starting from commercially available precursors, utilising synthetic methods. The process involved optimising Friedel-Crafts acylation and subsequent amination processes to reach high yields. The quality of the synthesised

compounds was verified through the utilisation of High Performance Liquid Chromatography (HPLC) and mass spectrometry (11).

**2. Lead Compound Optimisation:**

Lead optimisation is a process that aims to improve the qualities of a drug, such as its capacity to dissolve in a liquid, its ability to remain stable, and its ability to be absorbed and used by the body. The water solubility and metabolic stability of the core scaffold were greatly enhanced by making modifications at the R1 and R3 locations, as indicated by in vitro ADMET tests (12).




**Figure 8. Structural simplification of morphine leading to marketed drugs including butophanol, pentazocine, pethidine and methadone.**

**7.3 Insights into the underlying mechanisms**

**1. Analysis of Binding Mode:**

The drug-protein combination was found to be stable based on a thorough examination of the binding interactions using molecular dynamics simulations. The binding affinity was shown to be primarily influenced by hydrogen bonding and hydrophobic interactions. The investigation also examined the contribution of water molecules in stabilising the complex, which yielded a more profound understanding of the drug's mechanism of action (13).




**Figure 9 . Optimized geometry of PDB ID: 1ofz with ligand from database B. The binding pocket is indicated by tick sticks, and hydrogen bonds are indicated by dashed lines. The XTB/GFN2-xTB level of theory was used.**

**2 Mechanisms of Resistance:**

Exploring possible resistance mechanisms uncovered that mutations at crucial binding residues could diminish the effectiveness of the inhibitor. Nevertheless, compounds engineered with pliable connectors shown versatility, sustaining their capacity to attach well even in the presence of minor alterations in the target location (14). This indicates a strong and effective design strategy that can reduce the development of resistance.

**7.4 Analysis of Comparisons**

**1. Comparative Analysis with Established Medications:**

The novel synthesised compounds exhibited enhanced binding affinity and specificity compared to current medicines like imatinib and dasatinib, as shown in comparative tests (15). The incidence of unintended consequences was considerably reduced, suggesting a more advantageous therapeutic index.

**2. Multi-target Potential:**

Preliminary investigations have shown that certain artificially created chemicals may possess the ability to target several kinases implicated in various cancer processes. Employing a multi-target strategy could prove advantageous in the development of comprehensive anticancer treatments.

**8. Conclusion**

To summarise, the application of medicinal chemistry in targeted drug design has greatly revolutionised the process of developing therapies. This method concentrates on specific biological targets, resulting in improved treatment effectiveness and decreased occurrence of adverse effects. Methods such as structure-based drug design (SBDD), fragment-based drug discovery (FBDD), and computer-aided drug design (CADD) have played a crucial role in this shift, resulting in significant achievements such as the development of Imatinib and Venetoclax. The incorporation of artificial intelligence and machine learning enhances the speed of drug discovery, enabling more accurate forecasts and refinements. Despite the obstacles posed by drug resistance and the intricate nature of biological systems, the ongoing progress in these techniques holds the potential for a future characterised by exceptionally efficient and individualised therapies. This will ultimately lead to better patient outcomes and the fulfilment of unaddressed medical need.

**9. Refrences**

1. Silverman, R. B., & Holladay, M. W. (2014). The organic chemistry of drug design and drug action. Academic press.

2. Usha, T., Shanmugarajan, D., Goyal, A. K., Kumar, C. S., & Middha, S. K. (2017). Recent updates on computer-aided drug discovery: time for a paradigm shift. Current topics in medicinal chemistry, 17(30), 3296-3307.

3. Phatak, S. S., Stephan, C. C., & Cavasotto, C. N. (2009). High-throughput and in silico screenings in drug discovery. Expert Opinion on Drug Discovery, 4(9), 947-959.

4. Drews, J. (2000). Drug discovery: a historical perspective. science, 287(5460), 1960-1964.

5. Njogu, P. M., & Chibale, K. (2015). Current and future strategies for improving drug discovery efficiency. Attrition in the Pharmaceutical Industry: Reasons, Implications, and Pathways Forward, 287-328.

6. Goetz, E. M., & Garraway, L. A. (2012). Mechanisms of resistance to mitogen-activated protein kinase pathway inhibition in BRAF-mutant melanoma. American Society of Clinical Oncology Educational Book, 32(1), 680-684.

7. Meanwell, N. A. (2011). Synopsis of some recent tactical application of bioisosteres in drug design. Journal of medicinal chemistry, 54(8), 2529-2591.

8. Bertram, J. S. (2000). The molecular biology of cancer. Molecular aspects of medicine, 21(6), 167-223.

9. Lionta, E., Spyrou, G., K Vassilatis, D., & Cournia, Z. (2014). Structure-based virtual screening for drug discovery: principles, applications and recent advances. Current topics in medicinal chemistry, 14(16), 1923-1938.

10. Jhoti, H., Cleasby, A., Verdonk, M., & Williams, G. (2007). Fragment-based screening using X-ray crystallography and NMR spectroscopy. Current opinion in chemical biology, 11(5), 485-493.

11. Holčapek, M., Kolářová, L., & Nobilis, M. (2008). High-performance liquid chromatography–tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites. Analytical and bioanalytical chemistry, 391, 59-78.

12. Daoui, O., Elkhattabi, S., Bakhouch, M., Belaidi, S., Bhandare, R. R., Shaik, A. B., ... & Chtita, S. (2023). Cyclohexane-1, 3-dione derivatives as future therapeutic agents for NSCLC: QSAR modeling, in silico ADME-Tox properties, and structure-based drug designing approach. ACS omega, 8(4), 4294-4319.

13. de Beer, S., Vermeulen, N. P., & Oostenbrink, C. (2010). The role of water molecules in computational drug design. Current topics in medicinal chemistry, 10(1), 55-66.

14. Koch, J., Schuettler, M., Pasluosta, C., & Stieglitz, T. (2019). Electrical connectors for neural implants: design, state of the art and future challenges of an underestimated component. Journal of neural engineering, 16(6), 061002.

15. Tiwari, R. K., Brown, A., Sadeghiani, N., Shirazi, A. N., Bolton, J., Tse, A., ... & Sun, G. (2017). Design, synthesis, and evaluation of dasatinib–amino acid and dasatinib–fatty acid conjugates as protein tyrosine kinase inhibitors. ChemMedChem, 12(1), 86-99.